Skip to main content

Type2diabetes

Metabolic Diseases
5
Pipeline Programs
9
Companies
7
Clinical Trials
2 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 6 programs with unclassified modality

Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.

$70.5B marketMature↑ Growing30 products15 companies

Key Trends

  • GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
  • SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
  • Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins

Career Verdict

Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
#2OZEMPICGrowing
$9.2B
Novo Nordisk·Peak12.4yr
#3JARDIANCEGrowing
$8.8B
#5FARXIGAGrowing
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

FXa Inhibitors (Anticoagulants)
$18.3B(26%)

stable, mature franchise

GLP-1 Agonists
$18.2B(26%)

rapid growth, expanding indications

SGLT2 Inhibitors
$9.4B(13%)

growing, cardio-renal expansion

Insulin Analogs
$7.8B(11%)

stable, generics pressure

DPP-4 Inhibitors
$5.4B(8%)

declining, patent cliff 2027

Career Outlook

Growing

Metabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.

Breaking In

Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.

For Experienced Professionals

Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.

In-Demand Skills

Commercial acumen and healthcare economics (GLP-1 market dynamics)Regulatory affairs (label expansion, indication creep for SGLT2/GLP-1)Digital health and CGM/insulin device experienceReal-world evidence generation and health outcomes research

Best For

Brand Manager (peak-cycle GLP-1 products)Medical Science Liaison (cardio-renal expansion)Market Access / Health Economics (SGLT2 outcomes)Commercial Operations (launch support for next-gen)

Hiring Landscape

$153K-$274K

Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.

574
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

270Growing
154Growing
42Stable
38Stable

By Department

Commercial(29%)
$220K
Engineering(22%)
$197K
Manufacturing(8%)
$274K
Clinical Operations(4%)
$153K

Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.

On Market (1)

Approved therapies currently available

AstraZeneca
FARXIGAApproved
dapagliflozin
AstraZeneca
oral2014
4.3B Part D

Competitive Landscape

7 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
DapagliflozinPhase 4Small Molecule1 trial
Active Trials
NCT06054035Recruiting170Est. Sep 2027
Chong Kun Dang Pharmaceutical
1 program
1
CKD-393Phase 11 trial
Active Trials
NCT05347576Completed31Est. May 2022
Pegbio
PegbioChina - Hangzhou
1 program
1
PB119Phase 11 trial
Active Trials
NCT05328843Unknown24Est. Oct 2022
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
ThiaminePhase 11 trial
Active Trials
NCT06322212Recruiting52Est. Mar 2027
Dexcom
DexcomCA - San Diego
1 program
Dexcom G6 CGMN/A1 trial
Active Trials
NCT05370612Completed16Est. Oct 2024
Vicore Pharma
Vicore PharmaSweden - Stockholm
1 program
C21PHASE_11 trial
Active Trials
NCT05831644Completed11Est. Jun 2023
Hua Medicine
Hua MedicineChina - Shanghai
1 program
Dorzagliatin tabletsPHASE_41 trial
Active Trials
NCT06263348Unknown2,000Est. Apr 2026

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
Hua MedicineDorzagliatin tablets
AstraZenecaDapagliflozin
Angeles TherapeuticsThiamine
Vicore PharmaC21
PegbioPB119
Chong Kun Dang PharmaceuticalCKD-393
DexcomDexcom G6 CGM

Clinical Trials (7)

Total enrollment: 2,304 patients across 7 trials

NCT06263348Hua MedicineDorzagliatin tablets

A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes

Start: Dec 2023Est. completion: Apr 20262,000 patients
Phase 4Unknown

SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

Start: Oct 2023Est. completion: Sep 2027170 patients
Phase 4Recruiting

Type 2 Diabetes and Blood Brain Barrier Improvement

Start: Aug 2024Est. completion: Mar 202752 patients
Phase 1Recruiting

A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes

Start: Mar 2023Est. completion: Jun 202311 patients
Phase 1Completed

Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function

Start: May 2022Est. completion: Oct 202224 patients
Phase 1Unknown

A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions

Start: Apr 2022Est. completion: May 202231 patients
Phase 1Completed
NCT05370612DexcomDexcom G6 CGM

AT GOAL: Adopting Technology for Glucose Optimization and Lifestyle in Pregnancy

Start: Aug 2022Est. completion: Oct 202416 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 2,304 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.